7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Insulin Resistance D007333 99 associated lipids
Weight Gain D015430 101 associated lipids
Glioma D005910 112 associated lipids
Hypertension D006973 115 associated lipids
Inflammation D007249 119 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Cundy T et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. 2002 Hum. Mol. Genet. pmid:12189164
Williamson E et al. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. 2002 J. Immunol. pmid:12244151
Lee SK et al. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. 2002 J. Immunol. pmid:12193704
Ferrer Cañabate J et al. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?]. 2002 An Med Interna pmid:12244784
Chen XW et al. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. 2002 Biochem. Biophys. Res. Commun. pmid:12150965
Katagiri T and Takahashi N Regulatory mechanisms of osteoblast and osteoclast differentiation. 2002 Oral Dis pmid:12108759
Lee SK and Lorenzo JA Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. 2002 Bone pmid:12110442
Shioi A et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. 2002 Circ. Res. pmid:12114316
Granchi D et al. Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. 2002 Biomaterials pmid:12013183
Li X et al. Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. 2002 Prostaglandins Other Lipid Mediat. pmid:12013525
Bosshart H Expression of survival receptors in Hodgkin disease cell lines. 2002 Blood pmid:12001908
Ono K et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. 2002 J. Bone Miner. Res. pmid:12009007
Iida-Klein A et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. 2002 J. Bone Miner. Res. pmid:12009011
Jain RG and Lenhard JM Select HIV protease inhibitors alter bone and fat metabolism ex vivo. 2002 J. Biol. Chem. pmid:11937496
Rogers A et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. 2002 J. Clin. Endocrinol. Metab. pmid:12364420
Romas E et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. 2002 Am. J. Pathol. pmid:12368214
Standal T et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. 2002 Blood pmid:12351414
Yang SY et al. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. 2002 Arthritis Rheum. pmid:12355500
Cremer I et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. 2002 Blood pmid:12393586
Giuliani N et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. 2002 Blood pmid:12393684
Liao EY et al. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. 2002 J. Endocrinol. Invest. pmid:12398237
Kazama JJ et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. 2002 Nephrol. Dial. Transplant. pmid:12271009
Lee SW et al. TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. 2002 J. Biochem. Mol. Biol. pmid:12296995
Redlich K et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. 2002 Arthritis Rheum. pmid:11920416
Yang X et al. Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. 2002 Biochem. Biophys. Res. Commun. pmid:11779130
Saidenberg Kermanac'h N et al. Osteoprotegerin and inflammation. 2002 Apr-Jun Eur. Cytokine Netw. pmid:12101070
Jung K et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. 2002 Jul-Sep Int. J. Biol. Markers pmid:12408468
Liu JZ et al. [Expression of human osteoprotegerin gene in E. Coli and bioactivity analysis of expression product]. 2003 Zhonghua Wai Ke Za Zhi pmid:14680558
Yamada Y et al. Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. 2003 Mol. Genet. Metab. pmid:14680982
Nakatsuka K et al. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. 2003 J. Bone Miner. Res. pmid:12929927
Li JP and Ling JQ [Tumor necrosis factor and lipopolysaccharide affect periodontal ligament cells expressing osteoprotegerin in vitro]. 2003 Zhonghua Kou Qiang Yi Xue Za Zhi pmid:12930661
Schett G et al. The role of osteoprotegerin in arthritis. 2003 Arthritis Res. Ther. pmid:12932284
Stilgren LS et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2003 Calcif. Tissue Int. pmid:14667132
Karsdal MA et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. 2003 J. Biol. Chem. pmid:12933809
Okada T et al. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. 2003 Clin. Exp. Metastasis pmid:14669795
Benevolenskaia LI [Issues of osteoporosis in present-day medicine]. 2003 Vestn. Akad. Med. Nauk SSSR pmid:12934464
Gannagé-Yared MH et al. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. 2003 J. Endocrinol. Invest. pmid:14669830
Sugatani T et al. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. 2003 J. Cell. Biochem. pmid:12938156
Ashcroft AJ et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. 2003 Immunity pmid:14670302
Min JK et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. 2003 J. Biol. Chem. pmid:12893832
Chong B et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. 2003 J. Bone Miner. Res. pmid:14672344
Teitelbaum SL and Ross FP Genetic regulation of osteoclast development and function. 2003 Nat. Rev. Genet. pmid:12897775
Si AI et al. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. 2003 J. Cell. Biochem. pmid:12898514
Nitta K et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. 2003 Am. J. Kidney Dis. pmid:12900812
Fizazi K et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. 2003 Clin. Cancer Res. pmid:12855635
Sezer O et al. RANK ligand and osteoprotegerin in myeloma bone disease. 2003 Blood pmid:12424190
Yamada T et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. 2003 Blood pmid:12411305
Smith MD et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. 2003 Ann. Rheum. Dis. pmid:12634226
Sakurai A et al. Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. 2003 Infect. Immun. pmid:14500523
Kim HH et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. 2003 FASEB J. pmid:14500543
Su X et al. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. 2003 Zhonghua Nei Ke Za Zhi pmid:14636471
Takayanagi H [Crosstalk between the immune and skeletal system]. 2003 Ryumachi pmid:14598653
Cho TJ et al. Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. 2003 Arthritis Rheum. pmid:14558090
von Tirpitz C et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. 2003 Eur J Gastroenterol Hepatol pmid:14560148
Kido S et al. Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. 2003 Bone pmid:12810169
Barillé-Nion S and Bataille R New insights in myeloma-induced osteolysis. 2003 Leuk. Lymphoma pmid:14565645
Kudlacek S et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. 2003 Bone pmid:12810175
Mandelin J et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. 2003 J Bone Joint Surg Br pmid:14653607
Ikeda T et al. Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. 2003 Pathol. Int. pmid:12828610
Malyszko J et al. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. 2003 Transplant. Proc. pmid:14529897
Crotti T et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. 2003 J. Periodont. Res. pmid:12828654
Ren W et al. Distinct gene expression of receptor activator of nuclear factor-kappaB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. 2003 Biomaterials pmid:14530078
Tazoe M et al. Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. 2003 Arch. Oral Biol. pmid:12828991
Wiethe C et al. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. 2003 J. Immunol. pmid:14530334
Wiethe C et al. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. 2003 J. Immunol. pmid:12626542
Wagner EF and Matsuo K Signalling in osteoclasts and the role of Fos/AP1 proteins. 2003 Ann. Rheum. Dis. pmid:14532157
Ueland T et al. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. 2003 J. Clin. Endocrinol. Metab. pmid:12629078
Ueland T et al. Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. 2003 Bone pmid:14555269
Schoppet M et al. Increased osteoprotegerin serum levels in men with coronary artery disease. 2003 J. Clin. Endocrinol. Metab. pmid:12629080
Han W et al. Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. 2003 Biotechnol. Appl. Biochem. pmid:12630898
Koshihara Y et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. 2003 J. Endocrinol. pmid:12630919
Alvarez L et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. 2003 Arthritis Rheum. pmid:12632438
Cheung J et al. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. 2003 J. Endocrinol. pmid:12773123
Nakamura H et al. Suppression of osteoblastic phenotypes and modulation of pro- and anti-apoptotic features in normal human osteoblastic cells under a vector-averaged gravity condition. 2003 J. Med. Dent. Sci. pmid:12968638
Viereck V et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. 2003 J. Clin. Endocrinol. Metab. pmid:12970288
Yamagami H et al. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. 2003 Biochem. Pharmacol. pmid:12948861
Srivastava S et al. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. 2003 J. Biol. Chem. pmid:12952963
Lee HA et al. Bumetanide, the specific inhibitor of Na+-K+-2Cl- cotransport, inhibits 1alpha,25-dihydroxyvitamin D3-induced osteoclastogenesis in a mouse co-culture system. 2003 Exp. Physiol. pmid:12955156
Yorke R et al. Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. 2003 Eur. J. Cancer pmid:12957466
Kaneyama K et al. Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. 2003 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:12973279
Lee ZH and Kim HH Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. 2003 Biochem. Biophys. Res. Commun. pmid:12745060
Boyle WJ et al. Osteoclast differentiation and activation. 2003 Nature pmid:12748652
Terpos E et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. 2003 Blood pmid:12689925
Zheng B et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. 2003 Blood pmid:12689928
Clohisy D Cellular mechanisms of osteolysis. 2003 J Bone Joint Surg Am pmid:12540662
Vanderkerken K et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. 2003 Cancer Res. pmid:12543775
Yu Q et al. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. 2003 J. Immunol. pmid:12574344
Rifas L et al. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. 2003 J. Cell. Biochem. pmid:12577299
Gordeladze JO and Reseland JE A unified model for the action of leptin on bone turnover. 2003 J. Cell. Biochem. pmid:12577304
Lubberts E et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. 2003 J. Immunol. pmid:12594294
Kato I et al. TRANCE together with IL-7 induces pre-B cells to proliferate. 2003 Eur. J. Immunol. pmid:12548564
Sordillo EM and Pearse RN RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003 Cancer pmid:12548579
Oyajobi BO and Mundy GR Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. 2003 Cancer pmid:12548580
Liu JZ et al. [The OPG/RANKL/RANK system and bone resorptive disease]. 2003 Sheng Wu Gong Cheng Xue Bao pmid:15971575
Liu JZ et al. [Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. 2003 Sheng Wu Gong Cheng Xue Bao pmid:15969033
Chagraoui H et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. 2003 Blood pmid:12506018
Lee Y et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. 2003 J. Orthop. Res. pmid:12507581
Sabokbar A et al. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. 2003 J. Orthop. Res. pmid:12507582
Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. 2003 Am. J. Hematol. pmid:12508266
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625

Table of Content